Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03945773
Title Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ipsen

renal cell carcinoma



Age Groups: adult | senior
Covered Countries FRA | ESP | DEU | AUT

No variant requirements are available.